Search research articles
Contact Us
Filters
Showing results (1-10 of 77) with videos related to
Page
of 8
Sort By:
Therapie
|
November 7, 1998
[Gene therapy: a review 6 years after the first trials in man. Round Table No 6 at Giens XIII]
M C Favrot
Pathologie-Biologie
|
January 1, 1988
[Why a growing interest in cancerology for residual disease? Is bone marrow a preferential site for detection?]
M C Favrot
La Revue Du Praticien
|
May 1, 1997
[The cancerous cell. Genetic abnormalities (oncogenes and anti-oncogenes), growth factors, apoptosis and dissemination factors, prognostic incidence]
M C Favrot
Human Gene Therapy
|
June 1, 1992
Retroviral gene therapy and its application in oncohematology
Y Merrouche, M C Favrot
Human Gene Therapy
|
October 1, 1992
Treatment of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin
M C Favrot, T Philip
Bone Marrow Transplantation
|
August 1, 1987
Detection of minimal malignant cell infiltration in the bone marrow of patients with solid tumours, non-Hodgkin lymphomas and leukaemias
M C Favrot, P Hervé
La Revue Du Praticien
|
November 1, 1993
[Neuroblastoma. Current clinical and therapeutic aspects. Contributions of modern biology]
O Hartmann, M C Favrot
Advances in Experimental Medicine and Biology
|
February 23, 1999
Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols
M C Favrot, I Puisieux
Pathologie-Biologie
|
February 1, 1989
Monoclonal antibodies in cancer therapy
M C Favrot, V Combaret, T Philip
The New England Journal of Medicine
|
December 23, 1993
CD44--a new prognostic marker for neuroblastoma
M C Favrot, V Combaret, C Lasset
Page
of 8
Search research articles
Search
Showing results (1-10 of 77) with videos related to
Sort By:
Page
of 8
Therapie
|
November 7, 1998
[Gene therapy: a review 6 years after the first trials in man. Round Table No 6 at Giens XIII]
M C Favrot
Pathologie-Biologie
|
January 1, 1988
[Why a growing interest in cancerology for residual disease? Is bone marrow a preferential site for detection?]
M C Favrot
La Revue Du Praticien
|
May 1, 1997
[The cancerous cell. Genetic abnormalities (oncogenes and anti-oncogenes), growth factors, apoptosis and dissemination factors, prognostic incidence]
M C Favrot
Human Gene Therapy
|
June 1, 1992
Retroviral gene therapy and its application in oncohematology
Y Merrouche, M C Favrot
Human Gene Therapy
|
October 1, 1992
Treatment of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin
M C Favrot, T Philip
Bone Marrow Transplantation
|
August 1, 1987
Detection of minimal malignant cell infiltration in the bone marrow of patients with solid tumours, non-Hodgkin lymphomas and leukaemias
M C Favrot, P Hervé
La Revue Du Praticien
|
November 1, 1993
[Neuroblastoma. Current clinical and therapeutic aspects. Contributions of modern biology]
O Hartmann, M C Favrot
Advances in Experimental Medicine and Biology
|
February 23, 1999
Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols
M C Favrot, I Puisieux
Pathologie-Biologie
|
February 1, 1989
Monoclonal antibodies in cancer therapy
M C Favrot, V Combaret, T Philip
The New England Journal of Medicine
|
December 23, 1993
CD44--a new prognostic marker for neuroblastoma
M C Favrot, V Combaret, C Lasset
Page
of 8